Women can now buy a test telling them if they carry variants of the BRCA1 and BRCA2 genes that raise their risk of breast cancer. That sounds like a welcome advance in medical technology. But the particular variants identified are very rare in the general population. If women buying the test don't understand that there is a risk they could be lulled into a false sense of security if they test negative. The test is being sold by 23andMe, a Californian company that has pioneered personal DNA analysis. The US Food and Drug Administration approved its sale last week, and if you have recently submitted your DNA to 23andMe, the results should be available online soon if you request them
© 2001-2024 Fundación Dialnet · Todos los derechos reservados